{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-001869","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.583544+00:00","generated_at":"2026-05-28T06:53:58.099500+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioXcel cuts CEO/CFO/CSO 2025 cash comp, grants stock options at $0.4713","bullets":["CEO Vimal Mehta's 2025 cash compensation reduced to $706,558; granted options for 660,000 shares at $0.4713.","CFO Richard Steinhart's cash comp reduced to $289,800; granted options for 270,000 shares.","CSO Frank Yocca's cash comp reduced to $290,500; granted options for 270,000 shares.","Options vest in 12 equal monthly installments; full acceleration on termination without cause or change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-001869","json":"https://secwatch.observer/filing/0001104659-25-001869.json","markdown":"https://secwatch.observer/filing/0001104659-25-001869.md","text":"https://secwatch.observer/filing/0001104659-25-001869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/0001104659-25-001869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/tm252221d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:53:58.099500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}